Accelerate Diagnostics reports Q3 2018 financial results
Nov 06, 2018
Revenue Placements up 40 Percent in U.S., Total Revenue up 64 Percent
TUCSON, Ariz., Nov. 6, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending September 30, 2018. The company reported a 40% increase in U.S. instruments placed under commercial contract, and revenue for the quarter of $1.3 million, an increase of 64% from the prior year quarter. Worldwide, revenue-generating instruments combined with those under evaluation agreements grew to 458 instruments.
- Antimicrobial Stewards from Tampa General Hospital see improvements after implementing Accelerate Pheno
Jun 09, 2020
- Clinicians at Moffitt Cancer Center make a difference for patients by optimizing antibiotic therapy earlier
Mar 06, 2020